Why the study?
Does nebivolol reduce the risk of cardiovascular complications and effectively lower blood pressure compared to other cardioselective beta-blockers in patients with arterial hypertension?
Does nebivolol reduce the risk of cardiovascular complications and effectively lower blood pressure compared to other cardioselective beta-blockers in patients with arterial hypertension?
Nebivolol is a highly selective, vasodilating beta-blocker that effectively lowers blood pressure and reduces cardiovascular complications in hypertensive patients without the metabolic and sexual side effects associated with traditional beta-blockers.
May support nebivolol consideration in hypertension for vasodilatory effects; leaves open confirmation of outcome benefits in prospective trials.
The international and domestic recommendations a group of beta-blockers is defined as first-line drugs for the treatment of arterial hypertension. Due to the expressed antihypertensive effect and high safety profile, their use can affect the severity of cardiovascular disease, the probability of complications. Among the representatives of beta-blockers, particular attention is being paid to drugs with vasodilating properties that have a high level of cardioselectivity. Nebivolol, as a vasodilating beta-blocker, participated in a series of large clinical studies, the results of which prove that its appointment to patients with arterial hypertension, compared with other cardioselective beta-blockers, leads to a marked reduction in the risk of complications, an effective reduction in blood pressure. The high safety profile is due to the lack of influence on the metabolism of lipids and carbohydrates, as well as on the erectile function of men.
No takes yet. Share an insight, caveat, or question.
O. М. Barna (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: